1. GSK takes RSV maternal vaccine candidate into phase 3 testing — FDA approves Alnylam's first-ever drug for rare kidney disease — FDA approves Roche's Xofluza to prevent flu spreading within families — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Aducanumab’s day of reckoning approaches

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 10:42 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Biogen’s fortunes depend on it getting approval for its Alzheimer’s candidate aducanumab. The company's lacklustre third-quarter results, announced Wednesday, emphasised this fact.

    The project faces an US FDA advisory committee on November 6, and the agency usually – but not always – follows the advice of its panels, so the outcome will be a big indicator of whether aducanumab will get the nod. But predicting which way the panel will swing is tough: on the one hand is aducanumab's unconvincing efficacy and safety, and on the other a dire lack of options for Alzheimer’s patients.

    article source